Compare Dow Jones Industrial Average ETF (DIA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Incyte Corporation — how do they compare? Dow Jones Industrial Average ETF trades at $516.07 (market cap $45.20B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Dow Jones Industrial Average ETF is the larger of the two by market cap, and Dow Jones Industrial Average ETF is more actively traded (4,095,368 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and Incyte Corporation for 33 Days on average.
| DIA | INCY | |
|---|---|---|
Market Cap | $45.20B | $22.85B |
Volume | 4,095,368 | 1,927,029 |
52-Week High | $542.79 | $129.93 |
52-Week Low | $451.37 | $83.80 |
Typical Hold Time | 104 Days | 33 Days |
Sector | — | Health |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA trades at $511.65 with minimal daily movement (+0.12%). Technical indicators show a bearish trend with selling pressure outweighing buying signals 13-4. The ETF maintains scheduled dividend distributions through 2026, with upcoming payments in September and October. Market breadth indicators suggest broader market weakness, though DIA's Dow Jones Industrial Average exposure provides blue-chip stability.
The ETF faces headwinds from technical bearishness and market volatility, but its diversified Dow exposure offers defensive characteristics. Key risks include Fed policy uncertainty and economic slowdown concerns. Dividend consistency provides income appeal, though valuation metrics remain unavailable for analysis.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
